Categorical change in T2 lesion volume and clinical outcomes in the Phase III FREEDOMS and its extension study, evaluating fingolimod in patients with relapsing-remitting multiple sclerosis.
Jeffery D, Cantogno EVD, Meier DP, Meinel M, Chin P, Shamim A
Mult Scler Relat Disord. 2014 Nov; 3(6):752-3. Epub 2014 Nov 21. PMID: 25891591.Abstract